Alkermes Inc. plc (ALKS)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 10:13 AM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ALKS in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ALKS and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ALKS at a glance
Key statistics
$7.40B
Market capitalization
- Previous close
- $44.11
- Open
- $44.25
- Day range
- $43.58 – $44.49
- Volume
- 298.4K
- Average volume (30 sessions)
- 2.38M
- Shares outstanding
- 167.76M
- Price / earnings
- 111.9
- Earnings per share
- $0.39
- Price / book
- 4.1
- Price / sales
- 4.4
- Beta (1 year, vs SPY)
- 0.79
Where the price sits in its year
52-week range
60% of the range
- Below the 52-week high
- -20.8%
- Above the 52-week low
- +63.3%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day average, above its 200-day
- 20-day average
- $41.08+7.4%
- 50-day average
- $44.85-1.6%
- 200-day average
- $39.87+10.6%
Between the conventional 30 and 70 bands.
+11.0%
1 week
-0.2%
1 month
-16.1%
3 months
+57.6%
Year to date
+45.8%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ALKS
ALKS on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ALKS.
See the plans →
Every planScreen names like ALKS
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ALKS
Put ALKS on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ALKS
See whether there is an open premium alert on ALKS, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ALKS headlines
- Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
Benzinga · Jan 12, 2026
- Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
Benzinga · Oct 22, 2025
- 6 Analysts Assess Alkermes: What You Need To Know - Benzinga
Benzinga · Jul 15, 2024
- 6 Analysts Assess Alkermes: What You Need To Know
Benzinga · May 23, 2024
- 7 Analysts Assess Alkermes: What You Need To Know
Benzinga · May 2, 2024
- Breaking Down Alkermes: 5 Analysts Share Their Views
Benzinga · Apr 9, 2024
- The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
Benzinga · Mar 19, 2024
SEC Form 4, most recent first
Insider filings
Reed Joshua
−4.1K
SVP, Chief Financial Officer · Shares withheld for tax
$163.21K · Oct 8, 2026
Reed Joshua
+9.2K
SVP, Chief Financial Officer · Option exercise
· Oct 8, 2026
Whitaker Anne Clem
+7.2K
Director · Grant or award
· Oct 7, 2026
Reed Joshua
−9.2K
SVP, Chief Financial Officer · Option exercise
· Oct 8, 2026
Whitaker Anne Clem
+18.0K
Director · Grant or award
· Oct 7, 2026
Gaffin David Joseph
−2.0K
EVP, CLO, Alkermes, Inc. · Open-market sale
$83.46K · Oct 2, 2026
Gaffin David Joseph
−2.0K
EVP, CLO, Alkermes, Inc. · Open-market sale
$97.65K · Sep 3, 2026
Hopkinson Craig C.
+5.0K
EVP R&D, Chief Medical Officer · Option exercise
$122.95K · Sep 1, 2026
About Alkermes Inc. plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Dublin 4, L2
- Employees
- 2,050
- Listed since
- Jul 16, 1991
- Website
- alkermes.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.